216 related articles for article (PubMed ID: 37491061)
21. Primary Pituitary Carcinoids Do Not Exist: A Reappraisal in the Era of Pituitary Neuroendocrine Tumours.
Armeni E; Alexandraki KI; Roncaroli F; Grossman AB
Arch Med Res; 2023 Dec; 54(8):102841. PubMed ID: 37394342
[TBL] [Abstract][Full Text] [Related]
22. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
23. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
24. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
25. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.
Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148
[TBL] [Abstract][Full Text] [Related]
27. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
28. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
29. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P
Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085
[TBL] [Abstract][Full Text] [Related]
31. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.
Tsukamoto T; Miki Y
Jpn J Radiol; 2023 Aug; 41(8):789-806. PubMed ID: 36826759
[TBL] [Abstract][Full Text] [Related]
32. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
33. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience.
Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E
Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981
[No Abstract] [Full Text] [Related]
34. Multiple tumorous lesions of the pituitary gland.
Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
[TBL] [Abstract][Full Text] [Related]
35. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
36. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
37. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
38. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB
Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667
[TBL] [Abstract][Full Text] [Related]
39. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
40. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
